BioSpace News Archive

ValGenesis, Inc. announced that a Canadian biotechnology company selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system – to digitize its corporate validation process.

Electromed, Inc. today announced that it will issue its financial results press release for the fiscal 2024 first quarter ended September 30, 2023, on Tuesday, November 7, 2023 after the close of the stock market.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on Tuesday, November 7, 2023, after the close of the market.

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ ® ) in individuals living with systemic lupus erythematosus (SLE).

Cascade Prodrug Inc. (Cascade), a private preclinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting hypoxia, today announced a poster presentation highlighting preclinical data for it’s lead candidate CPD100Li at the SITC 2023 Annual Meeting, being held November 3-5 in San Diego, CA.

Inimmune Corporation announced that it has entered a research collaboration with Boston Children’s Hospital to develop novel and innovative small molecule vaccine adjuvants.

Cognito Therapeutics, a late-stage developer of disease-modifying therapies to treat neurodegenerative disorders, announced today continued active treatment in the Phase 2 OVERTURE open label extension (OLE) study demonstrated durability and concordance of clinical and MRI benefits over 18 months in patients with Alzheimer’s disease (AD).

Prevencio, Inc. announces the presentation of patient data demonstrating that its Artificial Intelligence -driven HART® CVE blood test is highly accurate for risk assessment in patients with total blockage of a heart artery, also known as coronary Chronic Total Occlusion.

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announces that partner Boehringer Ingelheim dosed the first patient in a Phase 2 trial investigating BI 764532 (OBT620) for the treatment of small cell lung cancer (SCLC) and other neuroendocrine cancers.

Radiaction Medical, LTD announced that it has appointed industry veteran Christopher Barys to serve as its US President and Chief Commercial Officer.